Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question
Endocrine-Related Cancer, Exclusive Author Commentary

Reis LO – In the last few years and months, important advancements in prostate cancer treatment have been achieved. Nevertheless, these advances are measured in a few months of additional survival and under high costs, not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years, there is a huge potential for accessible and durable effect expansion and optimization of treatment, particularly with the current tendency of a more individual approach.

Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question Leonardo Oliveira Reis, MD, MSc, PhD Found at The equivalence of surgical and different pharmacological castrations has been contested, and it is of concern that most of the phase III studies for the Food and Drug Administration licensing of LHRH agonists were based on the previous 50 ng/dl castration level defined by the historical assay limitation, dated before 1996. Adding to this controversy is a cluster of evidence supporting the hypothesis ‘the lower the better when achieving castration levels of testosterone’, based on the data from second-line hormonal manipulation and its molecular basis [1]. Until now, the optimal serum testosterone level in patients under castration and the impact of its variations in patients under LHRH therapy remain uncertain. In the current scenario of advancements measured in a few months and under high costs, which are not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years [1], this denotes a huge potential for accessible and durable effect expansion and optimization of treatment, particularly for the current tendency of a more individual approach. We have previously highlighted [1] that although the androgen receptor (AR) is the major therapeutic target of prostate cancer (PCa), there are currently no clinical studies available in which the AR status was considered in the study design. Furthermore, to date, even with better understanding of the molecular pathways behind castration resistant prostate cancer (CRPC), no study on secondary hormonal treatment with strong methodology has shown a benefit in terms of survival, but most trials have been smaller and heavily biased for patients’ heterogeneity. Adding to this complex and challenging scenario is the fact recently confirmed by our group that the efficiency of the different available pharmacological castration solutions aimed at reaching castration levels, mainly for cutoff ? 20 ng/dl, can vary significantly; surprisingly, about half and one-third of patients did not achieve castration levels of 20 and 50 ng/dl respectively [2]. It is of concern that although in the last 2 years, three approved treatments based on Phase III trials have demonstrated modest survival improvements (measured in months) in CRPC [cabazitaxel (potent taxane able to bypass the main resistance mechanism to docetaxel drug efflux pump, P-glycoprotein 1; approved in 2010); sipuleucel-T (immunotherapeutic agent through dendritic cells; approved in 2010); and abiraterone (orally active, potent and irreversible inhibitor of CYP17 – a critical enzyme in androgen biosynthesis; approved in 2011)], palpable advancement in hormonal management has been scarce and underexplored [1,2]. The sequential responses to hormonal manipulation, known as secondary hormonal therapy, implies that AR signaling remains an important therapeutic target and also relies on the fact that CRPC is not necessarily androgen-independent and is susceptible to further hormonal manipulation [1]. Although an imperative clinical consideration, ineffective testosterone suppression (ITS) through hormonal escape is not recognized when serum testosterone is not systematically monitored, culminating in very scarce data analyzing the impact of serum testosterone levels and breakthrough increases in PCa clinical outcome. Abiraterone, effectively blocking the conversion of androgens from non-gonadal precursors, thus reducing testosterone to undetectable levels, has recently been proved to extend survival rates for men with metastatic CRPC who have progressive disease even after first-line chemotherapy treatment [1]. Furthermore, when defining CRPC, the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies, and are therefore fundamental predictors of survival in individual patients. There are unquestionably different molecular determinants on why one cancer would respond to possibly slightly higher androgen levels than another, and this presumably relates to how the AR is working. Current literature on the issue must be interpreted cautiously once they are not designed based on the above-mentioned rational and does not take into consideration the molecular basis, being obviously not powered to detect small differences in outcome, owing to patients’ heterogeneity and the relatively short median follow-up. Future studies must be based on the proposed rational, with the accurate design of a more individual approach with precise molecular targets, and very long follow-up periods, combined with well-defined and accurate oncological and survival primary outcomes. References: 1- Reis LO 2011 Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology [in press]. (doi:10.1007/s12032-011- 9991-z;PMID:21626233) 2- Silva ED, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO. 2012 Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. International Urology and Nephrology [in press]. (doi:10.1007/s11255-012-0134-z;PMID:22315155) Prof. Dr. Leonardo Oliveira Reis, MD, MSc, PhD Department of Surgery (Urology),?School of Medical Sciences,?University of Campinas, UNICAMP, Brazil. Professor?of Medicine (Urology),?Center for Life Sciences,?Pontifical Catholic University of Campinas,?PUC-Campinas, Brazil

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Nursing

See All >> Messages include industry-sponsored communications and special communications from MDLinx


Most Popular Nursing Articles

1 Vitamin D and sleep disorders Full Text Nature and Science of Sleep, August 13, 2014    Free full text    Clinical Article

2 Study identifies best way to treat neck pain Johns Hopkins Medicine, October 24, 2014

3 Metformin in chronic kidney disease: Time for a rethink Peritoneal Dialysis International, July 9, 2014    Clinical Article

4 Suffering from constipation? Self-acupressure can help UCLA Health System, November 19, 2014

5 Long-term associations of nut consumption with body weight and obesity American Journal of Clinical Nutrition, June 23, 2014    Clinical Article

6 Yogurt consumption, weight change and risk of overweight/obesity: The SUN cohort study Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Clinical Article

7 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 19, 2014    Clinical Article

8 Decreased ability to identify odors can predict death The University of Chicago Medical Center News, October 3, 2014

9 Yogurt and weight management American Journal of Clinical Nutrition, April 3, 2014    Review Article

10 UAB plans clinical trial for repurposed drug shown to reverse diabetes UAB Medicine, November 12, 2014

11 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

12 Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study American Journal of Clinical Nutrition, December 1, 2014    Evidence Based Medicine    Clinical Article

13 Associations of sugar and artificially sweetened soda and chronic kidney disease: A systematic review and meta-analysis Nephrology, September 24, 2014    Evidence Based Medicine    Review Article

14 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 12, 2014    Evidence Based Medicine    Clinical Article

15 Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-analysis European Journal of Cancer, August 7, 2014    Review Article

16 Dairy products, calcium, and prostate cancer risk: A systematic review and meta-analysis of cohort studies American Journal of Clinical Nutrition, November 26, 2014    Clinical Article

17 Association of tea consumption and the risk of oral cancer: A meta-analysis Oral Oncology , January 10, 2014    Evidence Based Medicine

18 Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis American Journal of Clinical Nutrition, June 19, 2014    Evidence Based Medicine    Review Article

19 Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: A mixed-treatment meta-analysis Full Text Clinical Cancer Research, November 27, 2013    Free full text    Evidence Based Medicine    Clinical Article

20 Chocolate consumption and risk of diabetes mellitus in the Physicians’ Health Study American Journal of Clinical Nutrition, December 10, 2014    Review Article

Indexed Journals in Nursing: Journal of Advanced Nursing, Journal of Clinical Nursing, Nurse Education In Practicemore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List